206 related articles for article (PubMed ID: 28757367)
1. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
Khoury P; Abiodun AO; Holland-Thomas N; Fay MP; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(1):190-195. PubMed ID: 28757367
[TBL] [Abstract][Full Text] [Related]
2. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD
Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
Stokes K; Yoon P; Makiya M; Gebreegziabher M; Holland-Thomas N; Ware J; Wetzler L; Khoury P; Klion AD
Clin Exp Allergy; 2019 Dec; 49(12):1598-1604. PubMed ID: 31657082
[TBL] [Abstract][Full Text] [Related]
5. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
7. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
8. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
9. The hypereosinophilic syndromes: current concepts and treatments.
Gleich GJ; Leiferman KM
Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
[TBL] [Abstract][Full Text] [Related]
10. Marked and persistent eosinophilia in the absence of clinical manifestations.
Chen YY; Khoury P; Ware JM; Holland-Thomas NC; Stoddard JL; Gurprasad S; Waldner AJ; Klion AD
J Allergy Clin Immunol; 2014 Apr; 133(4):1195-202. PubMed ID: 23987798
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
12. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM
Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179
[TBL] [Abstract][Full Text] [Related]
13. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
14. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
Klion A
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):326-331. PubMed ID: 30504328
[TBL] [Abstract][Full Text] [Related]
15. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract][Full Text] [Related]
16. Clinical analysis of hypereosinophilic syndrome first presenting with asthma-like symptoms.
Wei X; Li X; Wei Z; Zhang H; Deng J; Xing S; Zhang J
Ann Med; 2022 Dec; 54(1):11-21. PubMed ID: 34935570
[TBL] [Abstract][Full Text] [Related]
17. Benralizumab for
Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
[TBL] [Abstract][Full Text] [Related]
18. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
[TBL] [Abstract][Full Text] [Related]
19. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
20. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]